Patents by Inventor Huong T. Dang

Huong T. Dang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Endogenous and Non-Endogenous Versions of Human G Protein-Coupled Receptors
    Publication number: 20150153327
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown (“orphan GPCR receptors”), and most particularly to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: June 24, 2014
    Publication date: June 4, 2015
    Inventors: RUOPING CHEN, HUONG T. DANG, KEVIN P. LOWITZ
  • Endogenous and Non-Endogenous Versions of Human G Protein-Coupled Receptors
    Publication number: 20140162358
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown, and to mutated (non-endogenous) versions of the human. GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: June 27, 2013
    Publication date: June 12, 2014
    Inventors: RUOPING CHEN, ZHI LIANG CHU, HUONG T. DANG, KEVIN P. LOWITZ, CAMERON PRIDE
  • Endogenous and Non-Endogenous Versions of Human G Protein-Coupled Receptors
    Publication number: 20130309766
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown, and to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: June 27, 2013
    Publication date: November 21, 2013
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: RUOPING CHEN, ZHI LIANG CHU, HUONG T. DANG, KEVIN P. LOWITZ, CAMERON PRIDE
  • Endogenous and Non-Endogenous Versions of Human G Protein-Coupled Receptors
    Publication number: 20130165633
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown (“orphan GPCR receptors”), and most particularly to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: June 12, 2012
    Publication date: June 27, 2013
    Inventors: RUOPING CHEN, HUONG T. DANG, KEVIN P. LOWITZ
  • Nucleic acids encoding RUP3 and methods of using same
    Patent number: 8198049
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: June 12, 2012
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Ruoping Chen, Huong T. Dang, Chen W. Liaw, I-Lin Lin
  • HUMAN ORPHAN G PROTEIN-COUPLED RECEPTORS
    Publication number: 20110195431
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors.
    Type: Application
    Filed: December 2, 2010
    Publication date: August 11, 2011
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: Ruoping Chen, Huong T. Dang, Chen W. Liaw, I-Lin LIn
  • Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders
    Publication number: 20110177612
    Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.
    Type: Application
    Filed: September 13, 2010
    Publication date: July 21, 2011
    Inventors: David J. Unett, Ruoping Chen, Jeremy G. Richman, Daniel Connolly, Huong T. Dang, Bryan Choi, James Leonard, Yaron Hakak, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Kevin P. Lowitz
  • Nucleic acids encoding the GPCR, RUP3, and methods of use thereof
    Patent number: 7893235
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: February 22, 2011
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Ruoping Chen, Huong T. Dang, Chen W. Liaw, I-Lin Lin
  • Human G protein-coupled receptors for metabolic-related disorders
    Patent number: 7829298
    Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.
    Type: Grant
    Filed: August 31, 2004
    Date of Patent: November 9, 2010
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: David J. Unett, Ruoping Chen, Jeremy G. Richman, Daniel T. Connolly, Huong T. Dang, Bryan J. Choi, James N. Leonard, Yaron Hakak, Chen W. Liaw, Dominic P. Behan, Derek T. Chalmers, Michael R. Lerner, Kevin P. Lowitz
  • ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF HUMAN G PROTEIN-COUPLED RECEPTORS
    Publication number: 20100047846
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown (“orphan GPCR receptors”), and most particularly to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: August 5, 2009
    Publication date: February 25, 2010
    Inventors: Ruoping Chen, Huong T. Dang, Kevin P. Lowitz
  • Human orphan G protein-coupled receptors
    Publication number: 20080199889
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors.
    Type: Application
    Filed: August 20, 2007
    Publication date: August 21, 2008
    Inventors: Ruoping Chen, Huong T. Dang, Chen W. Liaw, I-Lin Lin
  • Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
    Publication number: 20040142377
    Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.
    Type: Application
    Filed: December 6, 2002
    Publication date: July 22, 2004
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: David J. Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly, Huong T. Dang, Bryan Choi, James Leonard, Yaron Hakak, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Kevin P. Lowitz
  • Endogenous and non-endogenous versions of human G protein-coupled receptors
    Publication number: 20040137563
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown (“orphan GPCR receptors”), and most particularly to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: December 16, 2002
    Publication date: July 15, 2004
    Inventors: Ruoping Chen, Huong T. Dang
  • Human orphan G protein-coupled receptors
    Publication number: 20030175891
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors.
    Type: Application
    Filed: March 21, 2003
    Publication date: September 18, 2003
    Inventors: Ruoping Chen, Huong T. Dang, Chen W. Liaw, I-Lin Lin
  • Endogenous and non-endogenous versions of human G protein-coupled receptors
    Publication number: 20030166148
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown (“orphan GPCR receptors”), and most particularly to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: December 16, 2002
    Publication date: September 4, 2003
    Inventors: Ruoping Chen, Huong T. Dang, Kevin P. Lowitz
  • Human orphan G protein-coupled receptors
    Publication number: 20030148450
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors.
    Type: Application
    Filed: October 17, 2002
    Publication date: August 7, 2003
    Inventors: Ruoping Chen, Huong T. Dang, Chen W. Liaw, I-Lin Lin
  • Endogenous and non-endogenous versions of human G protein-coupled receptors
    Publication number: 20030139588
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown, and to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: November 26, 2001
    Publication date: July 24, 2003
    Inventors: Ruoping Chen, Zhi Liang Chu, Huong T. Dang, Kevin P. Lowitz, Cameron Pride
  • Human orphan G protein-coupled receptors
    Publication number: 20030017528
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors.
    Type: Application
    Filed: June 6, 2001
    Publication date: January 23, 2003
    Inventors: Ruoping Chen, Huong T. Dang, Chen W. Liaw, I-Lin Lin
  • Non-endogenous, constitutively activated human G protein-coupled receptors
    Publication number: 20030018182
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown (“orphan GPCR receptors”), and most particularly to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: June 7, 2001
    Publication date: January 23, 2003
    Inventors: Dominic P. Behan, Karin Lehmann-Bruinsma, Derek T. Chalmers, Ruoping Chen, Huong T. Dang, Martin Gore, Chen W. Liaw, I-Lin Lin, Kevin Lowitz, Carol White
  • Endogenous and non-endogenous versions of human G protein-coupled receptors
    Publication number: 20020193584
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown, and to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: November 26, 2001
    Publication date: December 19, 2002
    Inventors: Ruoping Chen, Zhi Liang Chu, Huong T. Dang, Kevin P. Lowitz, Cameron Pride